{
    "clinical_study": {
        "@rank": "4725", 
        "arm_group": [
            {
                "arm_group_label": "levodopa and carbidopa", 
                "arm_group_type": "Experimental", 
                "description": "levodopa and carbidopa solution"
            }, 
            {
                "arm_group_label": "placebo to levodopa and carbidopa", 
                "arm_group_type": "Placebo Comparator", 
                "description": "saline"
            }
        ], 
        "brief_summary": {
            "textblock": "In this Phase I/IIa study, the effect of continuous subcutaneous administration of  LD/CD\n      solution (ND0612) on the safety and PK profile of LD will be examined."
        }, 
        "brief_title": "A Phase I/IIa Study of Safety, Tolerability and Plasma Concentration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "detailed_description": {
            "textblock": "Design: single center, double-blind, randomized, placebo-controlled, crossover study.\n\n      Study Drug: Subcutaneous (SC), ND0612 (LD/CD solution) or placebo (saline) to be\n      administered via a continuously via the CRONO Five SC pump. A 1-week washout period will\n      apply between the treatments.\n\n      Population: Eight (8) PD subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          -  Men and women with idiopathic Parkinson's disease\n\n          -  Subjects must experience motor fluctuations associated with LD/CD dosing\n\n          -  Modified Hoehn and Yahr stage < 5\n\n          -  Subjects must be taking optimized and stable levodopa/dopa decarboxylase inhibitor\n             therapy\n\n          -  Women must be postmenopausal, surgically sterilized, or using adequate birth control.\n             Women of childbearing potential must have a negative pregnancy test (serum beta-HCG)\n             at screening.\n\n          -  Subjects must be age 30 or older.\n\n          -  Subjects must be willing and able to give informed consent.\n\n        Main Exclusion Criteria:\n\n          -  Subjects with a clinically significant or unstable medical or surgical condition\n\n          -  Subjects with clinically significant psychiatric illness.\n\n          -  Pre-menopausal women, not using birth control method.\n\n          -  Subjects who have taken experimental medications within 60 days prior to baseline.\n\n          -  Subject who have undergone a neurosurgical intervention for Parkinson's disease\n             (e.g., pallidotomy, thalamotomy, transplantation and deep brain stimulation)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725802", 
            "org_study_id": "ND0612/002"
        }, 
        "intervention": [
            {
                "arm_group_label": "levodopa and carbidopa", 
                "intervention_name": "levodopa and carbidopa solution for SC administration", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo to levodopa and carbidopa", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Saline"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carbidopa", 
                "Levodopa"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Jerusalem", 
                    "country": "Israel"
                }, 
                "name": "Hadassah Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I/IIa, Single Dose, Single-centre, Randomized, Crossover, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Incidence and frequency of adverse events\nAdverse events reporting related to the ND0612 application, local safety score", 
                "measure": "Incidence and frequency of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "description": "Withdrawal rates and discontinuations due to adverse events", 
                "measure": "Withdrawal rate", 
                "safety_issue": "Yes", 
                "time_frame": "2 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725802"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "LD PK profile after oral LD dosing administered with or without ND0612:", 
            "measure": "LD Half life (t\u00bd ), time of LD plasma concentrations maintained above 1000 ng/ml, trough levels, Cmax, Tmax and AUC", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 days"
        }, 
        "source": "NeuroDerm Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "NeuroDerm Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}